Investing.comDoubao · 实盘不做把握 7/10不做原因:标的无直接敞口
北京时间·🕒 发布 20:48:37·⟳ 抓取 20:49:02 +25s·⚡ 决策 10-14 20:55:14 +6m12s·13.0 天前
INmune Bio与Quantum Computing Inc合作用量子计算+AI筛选XPro新适应症，无金额披露、盘前两股齐跌
合作本质是早期探索性数据分析服务，无金额、无里程碑、无收入或临床状态变化，对两家公司均无可量化基本面增量；盘前市场以下跌回应，两股均处下行通道，INMB流动性极差，无正期望edge。
📄 原文Investing.com↗ 原文
INmune Bio partners with Quantum Computing for drug research
U.S. consumer prices rise by 3.7% year-on-year in September BOCA RATON, Fla. and HOBOKEN, N.J. - INmune Bio Inc. (NASDA…
不做 Quantum Computing Inc.（QUBT.US）
无金额探索性合作PR，无收入弹性；盘前-2.6%负反应、股价下行通道，题材脉冲无基本面edge，不追多也无强空催化
不做 INmune Bio Inc.（INMB.US）
量子计算辅助适应症筛选不改变XPro临床状态与业绩，微盘流动性极差（日成交约42万美元），盘前续跌，无交易价值
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
量子计算公司与微盘生物科技的无金额探索性合作PR，不改变任何一方收入或临床价值；盘前两股齐跌、近期均为下跌趋势，属无materiality题材新闻，不做。
🔎 新鲜度:最早出现 2026-10-14 · 扩散 low · price-in 风险 low ↗
消息传播链
- 节点
- 节点
- 节点
- 节点
关键理由
- 无合同金额、里程碑或订单规模披露，无法建立收入/市值弹性，名义利好不构成可交易催化
- 盘前QUBT -2.6%、INMB -1.2%，市场未作正向重定价，追多缺乏确认
主要风险
- 量子计算题材盘中可能借消息情绪化脉冲（QUBT日成交额约6200万美元、股性活跃），但属无基本面支撑的投机波动
- 若后续披露实质付款或具体适应症发现需重估，当前公告不含此类信息
反向证据
- 做多前查反向 · 来源 web · 日期 2026-10-14 · 影响 invalidates
公开报道无合同金额、预付款或里程碑条款，无法建立多头基本面逻辑；两股盘前均跌、近期持续下行（QUBT近20日-12%、INMB近20日-26%）
检索:QUBT INMB collaboration contract value revenue terms milestone 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例缺失不改变AVOID：决策基于零materiality与负盘前反应，而非先例幅度
方向:无可核验首发先例面板；量子计算板块同类合作PR历史上多为短线脉冲后回落，但未取得满足首发锚要求样本，不定量使用
涨幅量级:不足以校准幅度
形态:盘前负反应与两股持续下行轨迹显示本次消息无正向定价
工具执行结果 · 成功 4 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 10 ms
{"result": "search_processed_events:agent query=`inmb qubt partnership quantum computing alzheimer drug discovery | inmune bio quantum computing collaboration xpro quantum dirac-3s | quantum computing inc first commercial pharmac`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agen - web_search 成功 doubao_search · 916 ms
豆包搜索结果（原始查询:INmune Bio Quantum Computing Inc collaboration XPro Dirac-3S press release；API SearchType:web） - stock_quote 成功 stock_tools HTTP · 403 ms
{ - stock_quote 成功 stock_tools HTTP · 577 ms
{
原文全文
展开原文 · 2,257 字
U.S. consumer prices rise by 3.7% year-on-year in September
BOCA RATON, Fla. and HOBOKEN, N.J. - INmune Bio Inc. (NASDAQ:INMB) and Quantum Computing Inc. (NASDAQ:QUBT) announced today a collaboration to apply quantum computing and artificial intelligence to identify new potential applications for XPro, INmune Bio’s investigational treatment for Alzheimer’s disease.
The partnership combines INmune Bio’s data from pre-clinical research and four clinical trials with QCi’s Dirac-3S quantum optimization machine. The companies plan to use quantum computing alongside AI and conventional data analytics to examine clinical and publicly available biomedical datasets, according to a press release statement.
The collaboration aims to identify diseases driven by the same biology that XPro targets and to prioritize those with potential for clinical success. XPro is designed to selectively inhibit soluble tumor necrosis factor, a protein involved in inflammation, while preserving other TNF functions important to the immune system.
"This collaboration allows us to examine patient populations and biomarkers most likely to predict responses by analyzing large data sets," said David Moss, Chief Executive Officer of INmune Bio.
The engagement represents QCi’s first commercial customer in the pharmaceutical and biotechnology market. The agreement includes options for additional work as INmune Bio advances its clinical development programs.
QCi will use its Dirac-3S entropy quantum optimization machine alongside AI and conventional analytics to look for patterns and relationships across datasets. The companies plan to compare results from quantum optimization with conventional statistical and machine-learning methods to evaluate which approaches are best suited to different parts of the analysis.
"INmune Bio has a complex scientific problem and a substantial body of clinical and biological data," said Yuping Huang, Chairman and Chief Executive Officer of QCi.
The work is intended to establish a repeatable discovery process through quantum computing that INmune Bio can use with additional datasets and potential disease indications.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
BOCA RATON, Fla. and HOBOKEN, N.J. - INmune Bio Inc. (NASDAQ:INMB) and Quantum Computing Inc. (NASDAQ:QUBT) announced today a collaboration to apply quantum computing and artificial intelligence to identify new potential applications for XPro, INmune Bio’s investigational treatment for Alzheimer’s disease.
The partnership combines INmune Bio’s data from pre-clinical research and four clinical trials with QCi’s Dirac-3S quantum optimization machine. The companies plan to use quantum computing alongside AI and conventional data analytics to examine clinical and publicly available biomedical datasets, according to a press release statement.
The collaboration aims to identify diseases driven by the same biology that XPro targets and to prioritize those with potential for clinical success. XPro is designed to selectively inhibit soluble tumor necrosis factor, a protein involved in inflammation, while preserving other TNF functions important to the immune system.
"This collaboration allows us to examine patient populations and biomarkers most likely to predict responses by analyzing large data sets," said David Moss, Chief Executive Officer of INmune Bio.
The engagement represents QCi’s first commercial customer in the pharmaceutical and biotechnology market. The agreement includes options for additional work as INmune Bio advances its clinical development programs.
QCi will use its Dirac-3S entropy quantum optimization machine alongside AI and conventional analytics to look for patterns and relationships across datasets. The companies plan to compare results from quantum optimization with conventional statistical and machine-learning methods to evaluate which approaches are best suited to different parts of the analysis.
"INmune Bio has a complex scientific problem and a substantial body of clinical and biological data," said Yuping Huang, Chairman and Chief Executive Officer of QCi.
The work is intended to establish a repeatable discovery process through quantum computing that INmune Bio can use with additional datasets and potential disease indications.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
60d3c35170· 2026-10-14 20:55 · doubao / doubao-seed-evolving-latest-version · 策略包2226518bfdee当前